Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study.

Difoum, Francoise; Schernberg, Antoine; Vanquaethem, Hélène; Picchi, Hugo; Roy, Audrey Le; Vuagnat, Perrine; Helissey, Carole

Difoum, Francoise; Schernberg, Antoine; Vanquaethem, Hélène; Picchi, Hugo; Roy, Audrey Le; Vuagnat, Perrine; Helissey, Carole.

Affiliation

Difoum F; Clinical Research unit, Military Hospital Begin, Saint-Mandé, France.
Schernberg A; Clinical Research unit, Military Hospital Begin, Saint-Mandé, France.
Vanquaethem H; Department of Internal Medicine, Military Hospital Begin, Saint-Mandé, France.
Picchi H; Department of Medical oncology, Military Hospital Begin, Saint-Mandé, France.
Roy AL; Department of Medical oncology, Military Hospital Begin, Saint-Mandé, France.
Vuagnat P; Clinical Research unit, Military Hospital Begin, Saint-Mandé, France.
Helissey C; Clinical Research unit, Military Hospital Begin, Saint-Mandé, France.

Cancer Rep (Hoboken) ; 6(7): e1760, 2023 07.

Article in En | MEDLINE | ID: mdl-36494190

Subject(s)

Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Small Cell Lung Carcinoma; Humans; Female; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Immune Checkpoint Inhibitors/adverse effects; Small Cell Lung Carcinoma/drug therapy; Prognosis; Quality of Life; Antineoplastic Agents, Immunological/therapeutic use

Key words

immune-related adverse events; immunotherapy; lung cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Small Cell Lung Carcinoma / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Cancer Rep (Hoboken) Year: 2023 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google